Venus Remedies Ltd

NSE: VENUSREM · BSE: 526953 · Pharmaceuticals & Biotechnology · 21 announcements

Share price: ₹1,769.40
Market cap: ₹2,365 Cr
Revenue (annual): ₹769.6 Cr
Net profit (annual): ₹102.8 Cr
P/E (TTM): 20.4×Sector 47.3×
Promoter holding: 41.76%+0.00% QoQ
FII holding: 2.92%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Other Announcement 8 Financial Results 4 Management Change 2 Annual General Meeting 2 Regulatory Approval 1 Dividend 1 Business Update 1 Board Meeting Outcome 1 Board Meeting Date 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

1 announcement with these filters

22 May 2026 11:54 IST BSE

Regulatory Approval

Venus Remedies Regulatory Approval

Venus Remedies received Saudi FDA approval for Plerixafor, its first global oncology marketing authorization. This grants direct access to the GCC's largest pharmaceutical market.

Read the filing ↗